Cross Modulation between the Androgen Receptor Axis and Protocadherin-PC in Mediating Neuroendocrine Transdifferentiation and Therapeutic Resistance of Prostate Cancer

Castration-resistant prostate cancers (CRPCs) that relapse after androgen deprivation therapies (ADTs) are responsible for the majority of mortalities from prostate cancer (PCa). While mechanisms enabling recurrent activity of androgen receptor (AR) are certainly involved in the development of CRPC...

Full description

Bibliographic Details
Main Authors: Stéphane Terry, Pascale Maillé, Habiba Baaddi, Laurence Kheuang, Pascale Soyeux, Nathalie Nicolaiew, Jocelyn Ceraline, Virginie Firlej, Himisha Beltran, Yves Allory, Alexandre de la Taille, Francis Vacherot
Format: Article
Language:English
Published: Elsevier 2013-07-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S147655861380070X
id doaj-eb9b4698d2fe41548115725708ff0d71
record_format Article
spelling doaj-eb9b4698d2fe41548115725708ff0d712020-11-24T23:42:19ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022013-07-0115776177210.1593/neo.122070Cross Modulation between the Androgen Receptor Axis and Protocadherin-PC in Mediating Neuroendocrine Transdifferentiation and Therapeutic Resistance of Prostate CancerStéphane Terry0Pascale Maillé1Habiba Baaddi2Laurence Kheuang3Pascale Soyeux4Nathalie Nicolaiew5Jocelyn Ceraline6Virginie Firlej7Himisha Beltran8Yves Allory9Alexandre de la Taille10Francis Vacherot11INSERM, Unité 955, Créteil, FranceDépartement de Pathologie, Plateforme de Ressources Biologiques, Hôpital H. Mondor-A. Chenevier, AP-HP, Créteil, FranceINSERM, Unité 955, Créteil, FranceINSERM, Unité 955, Créteil, FranceINSERM, Unité 955, Créteil, FranceINSERM, Unité 955, Créteil, FranceFaculté de Médecine/Signalisation et Cancer de la Prostate/EA4438, Université Strasbourg, Strasbourg, FranceINSERM, Unité 955, Créteil, FranceDepartment of Medicine, WeillCornell Medical College, New York, NYINSERM, Unité 955, Créteil, FranceINSERM, Unité 955, Créteil, FranceINSERM, Unité 955, Créteil, France Castration-resistant prostate cancers (CRPCs) that relapse after androgen deprivation therapies (ADTs) are responsible for the majority of mortalities from prostate cancer (PCa). While mechanisms enabling recurrent activity of androgen receptor (AR) are certainly involved in the development of CRPC, there may be factors that contribute to the process including acquired neuroendocrine (NE) cell-like behaviors working through alternate (non-AR) cell signaling systems or AR-dependent mechanisms. In this study, we explore the potential relationship between the AR axis and a novel putative marker of NE differentiation, the human male protocadherin-PC (PCDH-PC), in vitro and in human situations. We found evidence for an NE transdifferentiation process and PCDH-PC expression as an early-onset adaptive mechanism following ADT and elucidate AR as a key regulator of PCDH-PC expression. PCDH-PC overexpression, in turn, attenuates the ligand-dependent activity of the AR, enabling certain prostate tumor clones to assume a more NE phenotype and promoting their survival under diverse stress conditions. Acquisition of an NE phenotype by PCa cells positively correlated with resistance to cytotoxic agents including docetaxel, a taxane chemotherapy approved for the treatment of patients with metastatic CRPC. Furthermore, knockdown of PCDH-PC in cells that have undergone an NE transdifferentiation partially sensitized cells to docetaxel. Together, these results reveal a reciprocal regulation between the AR axis and PCDH-PC signals, observed both in vitro and in vivo, with potential implications in coordinating NE transdifferentiation processes and progression of PCa toward hormonal and chemoresistance. http://www.sciencedirect.com/science/article/pii/S147655861380070X
collection DOAJ
language English
format Article
sources DOAJ
author Stéphane Terry
Pascale Maillé
Habiba Baaddi
Laurence Kheuang
Pascale Soyeux
Nathalie Nicolaiew
Jocelyn Ceraline
Virginie Firlej
Himisha Beltran
Yves Allory
Alexandre de la Taille
Francis Vacherot
spellingShingle Stéphane Terry
Pascale Maillé
Habiba Baaddi
Laurence Kheuang
Pascale Soyeux
Nathalie Nicolaiew
Jocelyn Ceraline
Virginie Firlej
Himisha Beltran
Yves Allory
Alexandre de la Taille
Francis Vacherot
Cross Modulation between the Androgen Receptor Axis and Protocadherin-PC in Mediating Neuroendocrine Transdifferentiation and Therapeutic Resistance of Prostate Cancer
Neoplasia: An International Journal for Oncology Research
author_facet Stéphane Terry
Pascale Maillé
Habiba Baaddi
Laurence Kheuang
Pascale Soyeux
Nathalie Nicolaiew
Jocelyn Ceraline
Virginie Firlej
Himisha Beltran
Yves Allory
Alexandre de la Taille
Francis Vacherot
author_sort Stéphane Terry
title Cross Modulation between the Androgen Receptor Axis and Protocadherin-PC in Mediating Neuroendocrine Transdifferentiation and Therapeutic Resistance of Prostate Cancer
title_short Cross Modulation between the Androgen Receptor Axis and Protocadherin-PC in Mediating Neuroendocrine Transdifferentiation and Therapeutic Resistance of Prostate Cancer
title_full Cross Modulation between the Androgen Receptor Axis and Protocadherin-PC in Mediating Neuroendocrine Transdifferentiation and Therapeutic Resistance of Prostate Cancer
title_fullStr Cross Modulation between the Androgen Receptor Axis and Protocadherin-PC in Mediating Neuroendocrine Transdifferentiation and Therapeutic Resistance of Prostate Cancer
title_full_unstemmed Cross Modulation between the Androgen Receptor Axis and Protocadherin-PC in Mediating Neuroendocrine Transdifferentiation and Therapeutic Resistance of Prostate Cancer
title_sort cross modulation between the androgen receptor axis and protocadherin-pc in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer
publisher Elsevier
series Neoplasia: An International Journal for Oncology Research
issn 1476-5586
1522-8002
publishDate 2013-07-01
description Castration-resistant prostate cancers (CRPCs) that relapse after androgen deprivation therapies (ADTs) are responsible for the majority of mortalities from prostate cancer (PCa). While mechanisms enabling recurrent activity of androgen receptor (AR) are certainly involved in the development of CRPC, there may be factors that contribute to the process including acquired neuroendocrine (NE) cell-like behaviors working through alternate (non-AR) cell signaling systems or AR-dependent mechanisms. In this study, we explore the potential relationship between the AR axis and a novel putative marker of NE differentiation, the human male protocadherin-PC (PCDH-PC), in vitro and in human situations. We found evidence for an NE transdifferentiation process and PCDH-PC expression as an early-onset adaptive mechanism following ADT and elucidate AR as a key regulator of PCDH-PC expression. PCDH-PC overexpression, in turn, attenuates the ligand-dependent activity of the AR, enabling certain prostate tumor clones to assume a more NE phenotype and promoting their survival under diverse stress conditions. Acquisition of an NE phenotype by PCa cells positively correlated with resistance to cytotoxic agents including docetaxel, a taxane chemotherapy approved for the treatment of patients with metastatic CRPC. Furthermore, knockdown of PCDH-PC in cells that have undergone an NE transdifferentiation partially sensitized cells to docetaxel. Together, these results reveal a reciprocal regulation between the AR axis and PCDH-PC signals, observed both in vitro and in vivo, with potential implications in coordinating NE transdifferentiation processes and progression of PCa toward hormonal and chemoresistance.
url http://www.sciencedirect.com/science/article/pii/S147655861380070X
work_keys_str_mv AT stephaneterry crossmodulationbetweentheandrogenreceptoraxisandprotocadherinpcinmediatingneuroendocrinetransdifferentiationandtherapeuticresistanceofprostatecancer
AT pascalemaille crossmodulationbetweentheandrogenreceptoraxisandprotocadherinpcinmediatingneuroendocrinetransdifferentiationandtherapeuticresistanceofprostatecancer
AT habibabaaddi crossmodulationbetweentheandrogenreceptoraxisandprotocadherinpcinmediatingneuroendocrinetransdifferentiationandtherapeuticresistanceofprostatecancer
AT laurencekheuang crossmodulationbetweentheandrogenreceptoraxisandprotocadherinpcinmediatingneuroendocrinetransdifferentiationandtherapeuticresistanceofprostatecancer
AT pascalesoyeux crossmodulationbetweentheandrogenreceptoraxisandprotocadherinpcinmediatingneuroendocrinetransdifferentiationandtherapeuticresistanceofprostatecancer
AT nathalienicolaiew crossmodulationbetweentheandrogenreceptoraxisandprotocadherinpcinmediatingneuroendocrinetransdifferentiationandtherapeuticresistanceofprostatecancer
AT jocelynceraline crossmodulationbetweentheandrogenreceptoraxisandprotocadherinpcinmediatingneuroendocrinetransdifferentiationandtherapeuticresistanceofprostatecancer
AT virginiefirlej crossmodulationbetweentheandrogenreceptoraxisandprotocadherinpcinmediatingneuroendocrinetransdifferentiationandtherapeuticresistanceofprostatecancer
AT himishabeltran crossmodulationbetweentheandrogenreceptoraxisandprotocadherinpcinmediatingneuroendocrinetransdifferentiationandtherapeuticresistanceofprostatecancer
AT yvesallory crossmodulationbetweentheandrogenreceptoraxisandprotocadherinpcinmediatingneuroendocrinetransdifferentiationandtherapeuticresistanceofprostatecancer
AT alexandredelataille crossmodulationbetweentheandrogenreceptoraxisandprotocadherinpcinmediatingneuroendocrinetransdifferentiationandtherapeuticresistanceofprostatecancer
AT francisvacherot crossmodulationbetweentheandrogenreceptoraxisandprotocadherinpcinmediatingneuroendocrinetransdifferentiationandtherapeuticresistanceofprostatecancer
_version_ 1725505028253286400